Skip to main content
. 2020 Jan 9;21(2):432. doi: 10.3390/ijms21020432

Figure 2.

Figure 2

Serum 5SCD and lactate dehydrogenase (LDH) levels at baseline and treatment with nivolumab (Nivo). Case a—Serum 5SCD at 41 days after the first administration of Nivo was decreased, while serum LDH remained stable. The result of Nivo was determined as a partial response. Case b—Serum 5SCD and LDH at 27 days after the first administration of Nivo were highly increased. The result of Nivo was determined as progressive disease. This Figure was modified with the consent of authors (Omodaka et al., [100]).